EP2429510B1 - Oil-in-water emulsion of mometasone and propylene glycol - Google Patents
Oil-in-water emulsion of mometasone and propylene glycol Download PDFInfo
- Publication number
- EP2429510B1 EP2429510B1 EP10721697.0A EP10721697A EP2429510B1 EP 2429510 B1 EP2429510 B1 EP 2429510B1 EP 10721697 A EP10721697 A EP 10721697A EP 2429510 B1 EP2429510 B1 EP 2429510B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oil
- mometasone
- water emulsion
- water
- propylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 title claims description 193
- 229960001664 mometasone Drugs 0.000 title claims description 57
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 title claims description 57
- 239000007764 o/w emulsion Substances 0.000 title claims description 47
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 79
- 229960002744 mometasone furoate Drugs 0.000 claims description 59
- 229960004063 propylene glycol Drugs 0.000 claims description 57
- 239000000839 emulsion Substances 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000003921 oil Substances 0.000 claims description 32
- 235000019198 oils Nutrition 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000003995 emulsifying agent Substances 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 17
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 11
- 239000008158 vegetable oil Substances 0.000 claims description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 8
- 229960003511 macrogol Drugs 0.000 claims description 8
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 239000003240 coconut oil Substances 0.000 claims description 7
- 235000019864 coconut oil Nutrition 0.000 claims description 7
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- -1 polyoxyethylene Polymers 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 59
- 235000013772 propylene glycol Nutrition 0.000 description 56
- 239000006071 cream Substances 0.000 description 54
- 239000012071 phase Substances 0.000 description 32
- 229940073610 elocon Drugs 0.000 description 20
- 239000002245 particle Substances 0.000 description 18
- 239000003925 fat Substances 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 12
- 239000008309 hydrophilic cream Substances 0.000 description 12
- 231100000401 skin blanching Toxicity 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 229940088679 drug related substance Drugs 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 235000019871 vegetable fat Nutrition 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 3
- 229940043234 carbomer-940 Drugs 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008387 emulsifying waxe Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000008308 lipophilic cream Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 150000004688 heptahydrates Chemical class 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000008362 succinate buffer Substances 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- CZPZNYOPLHCGPF-UHFFFAOYSA-N CCC(O)CC(C)O.OCCCCCCO Chemical compound CCC(O)CC(C)O.OCCCCCCO CZPZNYOPLHCGPF-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- WUAIVKFIBCXSJI-UHFFFAOYSA-N butane-1,3-diol;butane-1,4-diol Chemical compound CC(O)CCO.OCCCCO WUAIVKFIBCXSJI-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- YSPXNJODCGZWPD-UHFFFAOYSA-N pentane-1,5-diol Chemical compound OCCCCCO.OCCCCCO YSPXNJODCGZWPD-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention provides a novel pharmaceutical composition of mometasone or mometasone furoate in the form of an oil-in-water emulsion, notably a cream.
- the composition has excellent stability and therapeutic effect.
- mometasone furoate has delayed the development of efficacious, economic and cosmetically elegant topical formulation.
- mometasone creams on the market today are all based on water-in-oil emulsions.
- WO 91/08733 (Schering Corp) relates to an oil-in-water (o/w) emulsion comprising a lipophilic active drug substance (e.g. mometasone).
- a lipophilic active drug substance e.g. mometasone
- the examples show the necessity of using N-methyl-2-pyrrolidone in order to enhance the vasoconstrictor effect.
- propylene glycol is used in a concentration of 10% w/w.
- WO 2008/126076 (Perrigo Israel Pharmaceuticals Ltd.) relates to a low-dose mometasone formulation.
- Exemplary formulations are creams containing 0.075% mometasone, a polyol, a gelling agent an oily phase, and water.
- a low-dose mometasone formulation is desired in order to reduce the toxicity of a mometasone formulation. It is believed that a formulation of WO 2008/126076 has a relatively low systemic steroid absorption. No in vivo studies are reported.
- the present invention provides an oil-in-water emulsion (o/w) containing mometasone or mometasome furoate as an active drug substance. Moreover, the emulsion contains from 20 to 45 % w/w propylene glycol, i.e. 1,2-propane-diol, wherein a part of the active drug substance is present in undissolved form.
- an o/w emulsion of the present invention provides a bioavailability and a therapeutic effect of mometasone that is comparable to the marketed w/o emulsion (Elocon® cream).
- the general view has been that in order to achieve a suitable therapeutic response it is of utmost importance to have the active drug dissolved or solubilised in the composition.
- mometasone furoate it has thus, until now, been considered to have mometasone furoate dissolved in the formulation.
- the present inventors have found that it is not necessary to have all mometasone dissolved in an o/w emulsion in order to achieve a suitable therapeutic effect.
- mometasone or mometasone furoate and propylene glycol in a relatively high concentration enables the formulation of an o/w emulsion, wherein mometasone is at least partly dissolved in the formulation (as appears from the examples herein, mometasone furoate is partly dissolved in the formulation).
- mometasone furoate is partly dissolved in the formulation.
- a suitable weight ratio between propylene glycol and water in the o/w emulsion seems to be important for the once daily administration. It seems as if a too large or a too low ratio will not result in the desired effect and/or the desired bioavailability.
- Another factor that seems to be of importance is the presence of mometasone or mometasone furoate in micronised form. Normally, mometasone is not dissolved (or only partly dissolved) in a composition of the invention. The results reported herein indicate the importance of having undissolved mometasone in micronised from.
- 100% of the mometasone particles have a particle size of at the most 20 ⁇ m, 99% has a particle size of at the most 15 ⁇ m, and 80% has a particle size of at the most 5 ⁇ m when measured by means of a laser scattering method.
- no particle of mometasone should exceed 40 ⁇ m.
- Most particles (more than 80% and visually evaluated in the microscope) have a size between 10 and 20 ⁇ m.
- Eventual particle growth over time in the composition should not result in any particles exceeding 50 ⁇ m, when measured with light microscopy. Other factors may also influence the results such as the nature of the other ingredients employed.
- compositions of the present invention seem to be the weight ratio and particle size as discussed above.
- a suitable weight ratio between propylene glycol and water is from about 1:1 to about 1:3.
- mometasone e.g. mometasone furoate
- propylene glycol and water that is bioequivalent with the w/o Elocon® cream.
- a composition of the invention contains two phases, an aqueous phase, which is the continuous phase and an oil phase, which is the dispersed phase that is homogeneously distributed in the continuous phase (i.e. as generally seen in o/w emulsions).
- the active drug substance, mometasone or mometasone furoate is partly dissolved and partly present in the form of fine particles, notably in micronized form.
- the present invention provides an oil-in-water emulsion comprising mometasone (M) or mometasone furoate and propylene glycol of a concentration from 20 to 45% w/w, from about 20% w/w to 40% w/w, or from 20% to 30% w/w.
- M mometasone
- propylene glycol of a concentration from 20 to 45% w/w, from about 20% w/w to 40% w/w, or from 20% to 30% w/w.
- propylene glycol in o/w emulsions of mometasone is illustrated in the Examples herein.
- alkane-diols as well may be used in combination with propylene glycol, such as propylene glycol (1,2-propane-diol), butylene glycol (1,3-butane-diol), pentylene glycol (1,5-pentane-diol), and/or hexylene glycol (1-methyl-2,4-pentane-diol).
- propylene glycol, pentylene glycol or hexylene glycol is used in combination with propylene glycol the concentration of such diols may be from 1% w/w to 20% w/w (notably from 5% w/w to 20% w/w).
- incorporation of propylene glycol is very important in order to obtain the desired effect, and not only is it the incorporation of propylene glycol in the emulsion, but also the concentration of propylene glycol, either expressed as the concentration in the total emulsion, or, more specific, expressed as a weight ratio between propylene glycol and water.
- concentration of propylene glycol either expressed as the concentration in the total emulsion, or, more specific, expressed as a weight ratio between propylene glycol and water.
- the weight ratio between propylene glycol and water in the composition may be important, but also the ratio between propylene glycol and mometasone or a pharmaceutically acceptable derivative thereof may have impact on the therapeutic result.
- One or more of these factors are contemplated to be important for whether an emulsion can be obtained with suitable properties with respect to therapeutic effect.
- the concentration of mometasone or mometasone furoate in an emulsion of the present invention may be from 0.01% to 2% w/w, normally from 0.05% to 0.2% w/w, from 0.075% to 0.2% w/w such as 0.1 % w/w.
- mometasone or mometasone furoate is not fully dissolved. Accordingly, a part of mometasone or a pharmaceutically acceptable derivative thereof is present in undissolved form, typically from 25% to 35% w/w of the total amount of mometasone present in the emulsion. In order to improve the dispersibility of the undissolved mometasone as well as the absorption rate, mometasone should be employed in micronised form. As it appears from the examples herein, mometasone, e.g.
- mometasone furoate should be employed in micronised form, wherein 100% has a particle size of at the most 20 ⁇ m, 99% has a particle size of at the most 15 ⁇ m, and 80% has a particle size of at most 5 ⁇ m (when determined by laser microscopy). It is contemplated that during the manufacturing process, as described herein, mometasone furoate may partly dissolve, but it is not fully dissolved. This seems to be of importance in order to control the particle size in the final composition. If mometasone is fully dissolved during the manufacturing method, a risk will occur that the mometasone that precipitates in the composition has a too large particle size. Accordingly, it is envisaged that the mean particle size (and/or particle size distribution) of mometasone furoate employed is important in order to obtain reproducible therapeutic results.
- diols may be used in combination with propylene glycol.
- diols include butylene glycol, pentylene glycol or hexylene glycol. Specific examples include butane-1,3-diol, pentane-1,5-diol and 1-methyl-2, 4-pentadiol. It is envisaged that other diols also may be suitable for use in the present context provided that it is suitable and safe for topical use.
- the concentration of propylene glycol in an emulsion of the invention is from 20% to 45% w/w.
- concentration of propylene glycol is from 20% to 40% w/w such as from 20% to 30% w/w.
- the weight ratio between propylene glycol and water seems to be important in order to achieve the desired therapeutic effect.
- the weight ratio between propylene glycol and mometasone (M) may also be a useful parameter to decide the amount of alkane-diol in an emulsion of the invention.
- the lower limit is normally not less than 10, such as in a range of from 10 to 100 and the upper limit is normally 4500 or less such as in a range of from 600 to 4500.
- the ratio is 100 or more such as from 100 to 900 or from about 200 to about 450, and M is calculated as mometasone furoate.
- the weight ratio between propylene glycol and mometasone is from 200 to 300, such as 200, 225, 250, 275 or 300, and M is calculated as mometasone furoate.
- Propylene glycol % w/w Mometasone (calculated as furoate) % w/w Ratio I/II I II 20-45 0.01-2 10-4500 20-40 0.01-2 10-4000 20-30 0.01-2 10-3000 20-45 0.05-1 20-900 20-40 0.05-1 20-800 20-30 0.05-1 20-600 20-45 0.05-0.5 40-900 20-40 0.05-0.5 40-800 20-30 0.05-0.5 40-600 20-45 0.05-0.2 100-900 20-40 0.05-0.2 100-800 20-30 0.05-0.2 100-600
- the weight ratio between propylene glycol and mometasone is 100 or more such as, e.g. 100 or more or 200 or more, such as, e.g., from 100 to 900, from about 200 to about 500, and M is calculated as mometasone furoate.
- the weight ratio between propylene glycol and mometasone (M) is from 200 to 450, from 200 to 400, and M is calculated as mometasone furoate.
- the weight ratio between propylene glycol and mometasone (M) is from 200 to 300, such as 200, 225, 250, 275 or 300, and M is calculated as mometasone furoate.
- the weight ratio between propylene glycol and water is indicative of whether a suitable emulsion is obtained (with respect to therapeutic activity).
- the weight ratio is normally from 1:1 to about 1:3 such as from about 1:1.5 to about 1:2.5 or from 1:1.75 to 1:2.25.
- a suitable ratio is found to be about 1:2 or 1:2.1 when 25% propylene glycol is employed and from about 1:2.8 to 1:2.9 when 20% propylene glycol is employed.
- the invention is directed to an oil-in-water emulsion, wherein mometasone or a pharmaceutically acceptable derivative thereof is the sole therapeutically active ingredient.
- Further active ingredients may be added provided that the bioavailability and therapeutic effect of mometasone are not negatively affected.
- further active ingredients may not have any negative effect on the stability of the o/w emulsion.
- an emulsion is established by mixing an aqueous phase and an oil phase.
- the oil is present in droplets homogeneously dispersed in the aqueous phase.
- surface active agents or emulsifying agents are added.
- the oil phase comprises an oil selected from a group consisting of vegetable oils and fats, animal oils and fats, mineral oils, ester oils, silicon oils or waxes.
- the oil/fat is a vegetable oil/fat such as coconut oil, olive oil, sunflower oil and canola oil etc. Fats can be defined as bulk storage material produced by plants, animals and microorganisms that contain aliphatic moieties, such as fatty acid derivatives. These are mainly, but not entirely, mixtures of triglycerols (triglycerides) and are known as oils or fats depending on whether they are liquid or solid at room temperature.
- the term “oil” also includes “fat” and oil/fat may also be produced synthetically or semi-synthetically.
- the concentration of the oil/fat in the emulsion is from about 3 to about 30% w/w, notably from about 5 to about 15% w/w.
- stabilization of an oil-in-water emulsion according to the invention may suitably be carried out by adding one or more emulsifying agents.
- An emulsion of the present invention may therefore comprise one or more emulsifying agents.
- three emulsifying agents having a HLB (hydrophilic-lipophilic balance) in the range 3-20 one with a high HLB, i.e. a HLB of, from about 11 - 20 and two with a low HLB, i.e. a HLB of, from about 3 - 11, gives the desired result with respect to stability without compromising the therapeutic effect.
- HLB hydrophilic-lipophilic balance
- Suitable emulsifying agents for use in a composition of the invention may be selected from the group consisting of glycerol alkyl esters, macrogol alkyl esters, polyoxyethyleneglycol alkyl esters, fatty acids, polyoxyethylene sorbitan esters, polyoxyethylene alkyl ethers, galactolipids.
- Specific emulsifying agents for use in a composition of the invention are glycerol monostearate 40-55, macrogol stearate, and stearic acid.
- the concentration of each emulsifier when present in an emulsion according to the present invention ranges from 1-5% w/w.
- an oil-in-water emulsion according to the invention may comprise a viscosity-increasing agent.
- Viscosity-increasing agents suitable for use in an emulsion may be selected from the group consisting of fatty alcohols (concentration range: 5-15% of total emulsion) However, the concentration normally dependents on the specific type of fatty alcohol used and a person skilled in the art will know how to adjust the concentration of such specific concentrations to obtain the desired viscosity.
- a suitable viscosity-increasing agent is cetostearyl alcohol.
- the concentration of the viscosity-increasing agent in the form of a fatty alcohol ranges from 5% to 15 % w/w.
- An emulsion of the invention is intended for topical use, i.e. as a cream to apply on the skin.
- pH may be adjusted to a skin-friendly value taking into consideration stability issues relating to mometasone.
- a suitable pH is below 6 such as from about 3 to about 6 or from about 4.0 to about 5.0.
- pH may be adjusted by use of one or more pH adjusting agent, which is selected from the group consisting of hydrochloric acid, phosphoric acid, sodium hydroxide, citrate buffer, phosphate buffer, phthalate buffers, acetate buffers, succinate buffers.
- a citrate buffer has proved to be suitable.
- an emulsion of the present invention may contain one or more fragrances.
- Addition of a preservative agent is normally not required as propylene glycol itself has antimicrobial effect when it is added in a sufficient concentration.
- the invention relates to an oil-in-water emulsion having one of the following compositions:
- an oil-in-water emulsion according to the invention does not contain N-methyl-2-pyrrolidone.
- the present invention also provides a method for manufacturing of an oil-in-water emulsion of the invention.
- the procedure is detailed described in Example 1 and a person skilled in the art will understand that the individual ingredients mentioned can be replaced by the ingredients mentioned in Table 1 below having the same functionality and in the concentration ranges mentioned. More specifically, the method comprises
- the ingredients, included in the oil phase i) above, are typically an oil as described herein and all the ingredients that are soluble in the oil phase (apart from mometasone). Such ingredients may be one or more emulsifying agents, one or more viscosity-increasing agents, one or more preservatives, if present, optionally one or more fragrance agents or the like.
- the ingredients included in the aqueous phase is - apart from mometasone - water and ingredients that are soluble in water such as e.g.
- propylene glycol and, optionally one or more C 3 -C 6 alkane-diols, one or more pH regulating agents, if present, one or more water-soluble viscosity-increasing agents, if present, one or more fragrance agents, if present, one or more preservatives, if present, and the like.
- the complete composition of the 0.1 % mometasone furoate oil-in-water cream is given in table 1.
- Table 1 Complete composition of 0.1 % mometasone furoate oil-in-water cream.
- Emollient 30 - 300 Vegetable oil/fat, animal oil/fat, mineral oil, ester oil or wax, silicon oil Stearic acid 20
- Mometasone furoate is dispersed in a small portion of a propylene glycol and water mixture. The remaining parts of propylene glycol and water are mixed and heated to about 65°C together with sodium citrate and citric acid. Thereafter, the dispersion of mometasone furoate is added to the aqueous phase.
- the ingredients of the oil phase are mixed and heated to about 70°C.
- the oil phase is added to the aqueous phase.
- the emulsion is mixed and homogenized and thereafter the cream is cooled during stirring.
- the 0.1 % mometasone furoate oil-in-water cream is stable both chemically and physically, see table 2 and 3.
- Skin blanching has been evaluated to assess the topical bioavailability of the 0.1 % mometasone furoate oil-in-water cream given in Example 1, see Figure 1 .
- the blanching effect has been compared to Elocon® 0.1 % cream.
- Elocon® 0.1 % cream is a water-in-oil emulsion, containing 0.1 % mometasone furoate.
- figure 1 it can be seen that the skin blanching and thereby the bioavailability of the 0.1 % mometasone furoate oil-in-water cream is comparable to that of Elocon® 0.1 % cream.
- VCA vasoconstrictor assay
- the skin color was measured prior to treatment (baseline) and after 1, 2, 4, 6, 18 and 24 hours after the end of the treatment period with a Minolta Chroma-Meter CR-300.
- the total mean skin blanching was assessed as baseline corrected AUC for the tested creams according to figure 4 .
- the 0.1 % mometasone furoate oil-in-water cream has been challenge tested according to Ph. Eur. "Efficacy of Antimicrobial Preservation”.
- the o/w cream showed that the formulation satisfies criteria in Ph. Eur. 5.1.3.
- the product is self preserved and has antimicrobial properties.
- compositions of the present invention and Elocon® 0.1 % were tested as described in Example 2 above.
- the compositions of the invention had different weight ratios PG:W, namely from 1:1.6 to 1:2.1.
- the composition with the weight ratio 1:1.6 was in accordance with the composition described in Table 1 herein, but contained 20% w/w coconut; the content of water was reduced accordingly.
- the composition with the weight ratio 1:2.1 contained 25% propylene glycol and had a composition as described in Table 1 herein.
- Example 3 Composition Perrigo Mometasone furoate 0.1 % cream (comparative cream according to WO 2008/126076 )
- Formula B Comparative
- Formula C Invention) in patent WO2008/126076 Ingredients Concentration (wt%) Mometasone furoate 0.075 Xanthan gum 0.2 Carbomer 940 0.3 Dibasic sodium phosphate anhydrous (corresponding to 1.0 wt % heptahydrate) 0.53
- the water phase is prepared first: Xanthan gum and carbomer 940 are dispersed in purified water. Next dibasic sodium phosphate is mixed into the dispersion. Emulsifying wax and benzyl alcohol are added to the dispersion and heated.
- mometasone furoate is dissolved in heated propylene glycol.
- oily phase is prepared: Oleic acid, cetostearyl alcohol, and caprylic capric triglyceride are combined and mixed.
- the active solution and the oily phase are added to the water phase.
- the resulting emulsion is cooled. pH is adjusted with phosphoric acid.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Description
- The present invention provides a novel pharmaceutical composition of mometasone or mometasone furoate in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect.
- The exceptionally poor solubility of mometasone furoate has delayed the development of efficacious, economic and cosmetically elegant topical formulation. The existing mometasone creams on the market today are all based on water-in-oil emulsions.
- One of the most challenging tasks for formulators is to incorporate poorly water-soluble drugs into effective products. Improving the solubility of the lipophilic drugs is considered to improve the bioavailability of the product. Therefore, formulations where the active substance is in a dissolved state are generally preferred. Normally the active substance is in a solubilized form when permeating the skin. Therefore it is also generally considered as an advantage when the active substance is in a solubilized form in the topical formulation in order to obtain a suitable therapeutic response.
-
US patent No. 4,808,610 (Schering Corp) andUS patent No. 7,312,207 (Taro Pharmaceuticals) relate to mometasone containing compositions for topical use, wherein the composition is in the form of a water-in-oil (w/o) emulsion. -
WO 91/08733 -
WO 2008/126076 (Perrigo Israel Pharmaceuticals Ltd.) relates to a low-dose mometasone formulation. Exemplary formulations are creams containing 0.075% mometasone, a polyol, a gelling agent an oily phase, and water. A low-dose mometasone formulation is desired in order to reduce the toxicity of a mometasone formulation. It is believed that a formulation ofWO 2008/126076 has a relatively low systemic steroid absorption. No in vivo studies are reported. - The present invention provides an oil-in-water emulsion (o/w) containing mometasone or mometasome furoate as an active drug substance. Moreover, the emulsion contains from 20 to 45 % w/w propylene glycol, i.e. 1,2-propane-diol, wherein a part of the active drug substance is present in undissolved form.
- As it appears from the examples herein, an o/w emulsion of the present invention provides a bioavailability and a therapeutic effect of mometasone that is comparable to the marketed w/o emulsion (Elocon® cream). As briefly discussed in the introduction, the general view has been that in order to achieve a suitable therapeutic response it is of utmost importance to have the active drug dissolved or solubilised in the composition. Considering the lipid nature of mometasone furoate it has thus, until now, been considered to have mometasone furoate dissolved in the formulation. However, as discussed below, the present inventors have found that it is not necessary to have all mometasone dissolved in an o/w emulsion in order to achieve a suitable therapeutic effect.
- The present inventors have found that using mometasone or mometasone furoate and propylene glycol in a relatively high concentration (from 20% to 45% w/w) enables the formulation of an o/w emulsion, wherein mometasone is at least partly dissolved in the formulation (as appears from the examples herein, mometasone furoate is partly dissolved in the formulation). Moreover, it is possible to obtain an o/w emulsion with a similar therapeutic effect to that seen with Elocon® cream, i.e. the o/w emulsion only need to be applied once daily. To this end and as supported by the results reported herein, a suitable weight ratio between propylene glycol and water in the o/w emulsion seems to be important for the once daily administration. It seems as if a too large or a too low ratio will not result in the desired effect and/or the desired bioavailability. Another factor that seems to be of importance is the presence of mometasone or mometasone furoate in micronised form. Normally, mometasone is not dissolved (or only partly dissolved) in a composition of the invention. The results reported herein indicate the importance of having undissolved mometasone in micronised from. Thus, in general, 100% of the mometasone particles have a particle size of at the most 20 µm, 99% has a particle size of at the most 15 µm, and 80% has a particle size of at the most 5 µm when measured by means of a laser scattering method. When determining the particle size by means of light microscopy (which is the method preferred, when the particle size is measured in the final composition), no particle of mometasone should exceed 40 µm. Most particles (more than 80% and visually evaluated in the microscope) have a size between 10 and 20 µm. Eventual particle growth over time in the composition should not result in any particles exceeding 50 µm, when measured with light microscopy. Other factors may also influence the results such as the nature of the other ingredients employed. However, the two most important factors in compositions of the present invention seem to be the weight ratio and particle size as discussed above. A suitable weight ratio between propylene glycol and water is from about 1:1 to about 1:3. As illustrated in the examples, it is possible to obtain an emulsion with balanced content of mometasone (e.g. mometasone furoate), propylene glycol and water that is bioequivalent with the w/o Elocon® cream.
- A composition of the invention contains two phases, an aqueous phase, which is the continuous phase and an oil phase, which is the dispersed phase that is homogeneously distributed in the continuous phase (i.e. as generally seen in o/w emulsions). Moreover, the active drug substance, mometasone or mometasone furoate, is partly dissolved and partly present in the form of fine particles, notably in micronized form.
- More specifically, the present invention provides an oil-in-water emulsion comprising mometasone (M) or mometasone furoate and propylene glycol of a concentration from 20 to 45% w/w, from about 20% w/w to 40% w/w, or from 20% to 30% w/w. The use of propylene glycol in o/w emulsions of mometasone is illustrated in the Examples herein. It is contemplated that other alkane-diols as well may be used in combination with propylene glycol, such as propylene glycol (1,2-propane-diol), butylene glycol (1,3-butane-diol), pentylene glycol (1,5-pentane-diol), and/or hexylene glycol (1-methyl-2,4-pentane-diol). When butylene glycol, pentylene glycol or hexylene glycol is used in combination with propylene glycol the concentration of such diols may be from 1% w/w to 20% w/w (notably from 5% w/w to 20% w/w).
- As evident from the examples herein, incorporation of propylene glycol is very important in order to obtain the desired effect, and not only is it the incorporation of propylene glycol in the emulsion, but also the concentration of propylene glycol, either expressed as the concentration in the total emulsion, or, more specific, expressed as a weight ratio between propylene glycol and water. When an oil-in-water emulsion of the invention is applied to the skin, the water in the composition is subject to evaporation. Thus, not only the weight ratio between propylene glycol and water in the composition may be important, but also the ratio between propylene glycol and mometasone or a pharmaceutically acceptable derivative thereof may have impact on the therapeutic result. One or more of these factors are contemplated to be important for whether an emulsion can be obtained with suitable properties with respect to therapeutic effect.
- The concentration of mometasone or mometasone furoate in an emulsion of the present invention may be from 0.01% to 2% w/w, normally from 0.05% to 0.2% w/w, from 0.075% to 0.2% w/w such as 0.1 % w/w.
- In an emulsion according to the invention, mometasone or mometasone furoate is not fully dissolved. Accordingly, a part of mometasone or a pharmaceutically acceptable derivative thereof is present in undissolved form, typically from 25% to 35% w/w of the total amount of mometasone present in the emulsion. In order to improve the dispersibility of the undissolved mometasone as well as the absorption rate, mometasone should be employed in micronised form. As it appears from the examples herein, mometasone, e.g. mometasone furoate, should be employed in micronised form, wherein 100% has a particle size of at the most 20 µm, 99% has a particle size of at the most 15 µm, and 80% has a particle size of at most 5 µm (when determined by laser microscopy). It is contemplated that during the manufacturing process, as described herein, mometasone furoate may partly dissolve, but it is not fully dissolved. This seems to be of importance in order to control the particle size in the final composition. If mometasone is fully dissolved during the manufacturing method, a risk will occur that the mometasone that precipitates in the composition has a too large particle size. Accordingly, it is envisaged that the mean particle size (and/or particle size distribution) of mometasone furoate employed is important in order to obtain reproducible therapeutic results.
- As mentioned above, other diols may be used in combination with propylene glycol. Such diols include butylene glycol, pentylene glycol or hexylene glycol. Specific examples include butane-1,3-diol, pentane-1,5-diol and 1-methyl-2, 4-pentadiol. It is envisaged that other diols also may be suitable for use in the present context provided that it is suitable and safe for topical use.
- As mentioned above, the concentration of propylene glycol in an emulsion of the invention is from 20% to 45% w/w. In general, the concentration of propylene glycol is from 20% to 40% w/w such as from 20% to 30% w/w.
- As mentioned above, the weight ratio between propylene glycol and water seems to be important in order to achieve the desired therapeutic effect. Moreover, the weight ratio between propylene glycol and mometasone (M) may also be a useful parameter to decide the amount of alkane-diol in an emulsion of the invention. In the following table calculations of suitable ranges of the ratio are given. As seen from the table, the lower limit is normally not less than 10, such as in a range of from 10 to 100 and the upper limit is normally 4500 or less such as in a range of from 600 to 4500. Normally, the ratio is 100 or more such as from 100 to 900 or from about 200 to about 450, and M is calculated as mometasone furoate. Specifically, the weight ratio between propylene glycol and mometasone (M) is from 200 to 300, such as 200, 225, 250, 275 or 300, and M is calculated as mometasone furoate.
Propylene glycol % w/w Mometasone (calculated as furoate) % w/w Ratio I/II I II 20-45 0.01-2 10-4500 20-40 0.01-2 10-4000 20-30 0.01-2 10-3000 20-45 0.05-1 20-900 20-40 0.05-1 20-800 20-30 0.05-1 20-600 20-45 0.05-0.5 40-900 20-40 0.05-0.5 40-800 20-30 0.05-0.5 40-600 20-45 0.05-0.2 100-900 20-40 0.05-0.2 100-800 20-30 0.05-0.2 100-600 - Generally, the weight ratio between propylene glycol and mometasone (M) is 100 or more such as, e.g. 100 or more or 200 or more, such as, e.g., from 100 to 900, from about 200 to about 500, and M is calculated as mometasone furoate.
- Specifically, the weight ratio between propylene glycol and mometasone (M) is from 200 to 450, from 200 to 400, and M is calculated as mometasone furoate.
- In particular, the weight ratio between propylene glycol and mometasone (M) is from 200 to 300, such as 200, 225, 250, 275 or 300, and M is calculated as mometasone furoate.
- Moreover, the weight ratio between propylene glycol and water (PG:W) is indicative of whether a suitable emulsion is obtained (with respect to therapeutic activity). Thus, the weight ratio is normally from 1:1 to about 1:3 such as from about 1:1.5 to about 1:2.5 or from 1:1.75 to 1:2.25. In the examples a suitable ratio is found to be about 1:2 or 1:2.1 when 25% propylene glycol is employed and from about 1:2.8 to 1:2.9 when 20% propylene glycol is employed.
- In the literature, combinations of steroids with other active ingredients are described. However, as is evident from the examples herein, the invention is directed to an oil-in-water emulsion, wherein mometasone or a pharmaceutically acceptable derivative thereof is the sole therapeutically active ingredient. Further active ingredients may be added provided that the bioavailability and therapeutic effect of mometasone are not negatively affected. Moreover, further active ingredients may not have any negative effect on the stability of the o/w emulsion.
- As mentioned above, an emulsion is established by mixing an aqueous phase and an oil phase. In an oil-in-water emulsion, the oil is present in droplets homogeneously dispersed in the aqueous phase. In order to stabilize the emulsion against phase separation, surface active agents or emulsifying agents are added.
- In an emulsion of the present invention, the oil phase comprises an oil selected from a group consisting of vegetable oils and fats, animal oils and fats, mineral oils, ester oils, silicon oils or waxes. Notably, the oil/fat is a vegetable oil/fat such as coconut oil, olive oil, sunflower oil and canola oil etc. Fats can be defined as bulk storage material produced by plants, animals and microorganisms that contain aliphatic moieties, such as fatty acid derivatives. These are mainly, but not entirely, mixtures of triglycerols (triglycerides) and are known as oils or fats depending on whether they are liquid or solid at room temperature. In the present context, the term "oil" also includes "fat" and oil/fat may also be produced synthetically or semi-synthetically.
- The concentration of the oil/fat in the emulsion is from about 3 to about 30% w/w, notably from about 5 to about 15% w/w.
- As mentioned above, stabilization of an oil-in-water emulsion according to the invention may suitably be carried out by adding one or more emulsifying agents. An emulsion of the present invention may therefore comprise one or more emulsifying agents. As seen from the examples herein use of three emulsifying agents having a HLB (hydrophilic-lipophilic balance) in the range 3-20, one with a high HLB, i.e. a HLB of, from about 11 - 20 and two with a low HLB, i.e. a HLB of, from about 3 - 11, gives the desired result with respect to stability without compromising the therapeutic effect.
- Suitable emulsifying agents for use in a composition of the invention may be selected from the group consisting of glycerol alkyl esters, macrogol alkyl esters, polyoxyethyleneglycol alkyl esters, fatty acids, polyoxyethylene sorbitan esters, polyoxyethylene alkyl ethers, galactolipids.
Specific emulsifying agents for use in a composition of the invention are glycerol monostearate 40-55, macrogol stearate, and stearic acid. - The concentration of each emulsifier when present in an emulsion according to the present invention ranges from 1-5% w/w.
- Moreover, an oil-in-water emulsion according to the invention may comprise a viscosity-increasing agent. Viscosity-increasing agents suitable for use in an emulsion may be selected from the group consisting of fatty alcohols (concentration range: 5-15% of total emulsion) However, the concentration normally dependents on the specific type of fatty alcohol used and a person skilled in the art will know how to adjust the concentration of such specific concentrations to obtain the desired viscosity.
- As seen from the examples herein, a suitable viscosity-increasing agent is cetostearyl alcohol.
- In general, the concentration of the viscosity-increasing agent in the form of a fatty alcohol ranges from 5% to 15 % w/w.
- An emulsion of the invention is intended for topical use, i.e. as a cream to apply on the skin. Accordingly, pH may be adjusted to a skin-friendly value taking into consideration stability issues relating to mometasone. A suitable pH is below 6 such as from about 3 to about 6 or from about 4.0 to about 5.0. pH may be adjusted by use of one or more pH adjusting agent, which is selected from the group consisting of hydrochloric acid, phosphoric acid, sodium hydroxide, citrate buffer, phosphate buffer, phthalate buffers, acetate buffers, succinate buffers. In order to arrive at a pH below 6 or about 4.0-5.0, a citrate buffer has proved to be suitable.
- Moreover, an emulsion of the present invention may contain one or more fragrances. Addition of a preservative agent is normally not required as propylene glycol itself has antimicrobial effect when it is added in a sufficient concentration.
-
- Further examples are:
- An oil-in-water emulsion according to the invention containing:
- 0.05-0.2 % w/w of mometasone or mometasone furoate
- 20-45 % w/w of propylene glycol,
- 3-30 % w/w of a vegetable oil/fat,
- 1-15 % w/w of one or more emulsifying agents,
- optionally 0.1-1% w/w of a pH adjusting agent,
- optionally 5-15% w/w of a viscosity increasing agent,
- up to 100% w/w of water.
- An oil-in-water emulsion according to the invention containing:
- 0.06-0.15 % w/w of mometasone or mometasone furoate
- 20-40 % w/w of propylene glycol,
- 5-15 % w/w of a vegetable oil/fat,
- 1-10 % w/w of one or more emulsifying agents,
- 0.1-1% w/w of a pH adjusting agent to adjust pH of the emulsion to about 4-6, optionally 5-15% w/w of a viscosity increasing agent,
- up to 100% w/w of water.
- An oil-in-water emulsion according to the invention containing:
- 0.1 % w/w of mometasone or mometasone furoate
- from 20 to 30 % w/w of propylene glycol,
- from 5 to 10 % w/w of a vegetable oil/fat,
- from 5-10 % w/w of one or more emulsifying agents,
- 0.1-1% w/w of a pH adjusting agent to adjust pH of the emulsion to about 4-6,
- 5-10% w/w of a viscosity increasing agent,
- up to 100% w/w of water.
- Notably, an oil-in-water emulsion according to the invention does not contain N-methyl-2-pyrrolidone.
- The present invention also provides a method for manufacturing of an oil-in-water emulsion of the invention. The procedure is detailed described in Example 1 and a person skilled in the art will understand that the individual ingredients mentioned can be replaced by the ingredients mentioned in Table 1 below having the same functionality and in the concentration ranges mentioned. More specifically, the method comprises
- i) preparing the oil phase by mixing the ingredients that make up the oil phase and heating to a temperature of from 60 °C to 80 °C, notably from 65 °C to 75 °C such as about 70 °C,
- ii) preparing the aqueous phase by a) preparing a dispersion of mometasone or mometasone furoate in part of the aqueous phase, b) preparing the remaining part of the aqueous phase by dissolving the ingredients, optionally by heating to 55 °C to 75 °C, notably from 60 °C to 70 °C such as about 65 °C, and c) addition of the dispersion resulting from a) to the remaining part of the aqueous phase resulting from b) to obtain the aqueous phase,
- iii) transferring the oil phase i) to the aqueous phase ii) or optionally ii) to i)
- iv) mixing until an emulsion is obtained,
- v) optionally, subjecting the thus obtained emulsion to vacuum conditions,
- vi) optionally, homogenizing the emulsion optionally under vacuum conditions,
- vii) optionally, addition of one or more fragrance agents,
- viii) cooling the thus obtained emulsion.
- The ingredients, included in the oil phase i) above, are typically an oil as described herein and all the ingredients that are soluble in the oil phase (apart from mometasone). Such ingredients may be one or more emulsifying agents, one or more viscosity-increasing agents, one or more preservatives, if present, optionally one or more fragrance agents or the like. The ingredients included in the aqueous phase is - apart from mometasone - water and ingredients that are soluble in water such as e.g. propylene glycol and, optionally one or more C3-C6 alkane-diols, one or more pH regulating agents, if present, one or more water-soluble viscosity-increasing agents, if present, one or more fragrance agents, if present, one or more preservatives, if present, and the like.
- The invention is further illustrated in the following Figures and Examples without limiting the invention thereto.
-
-
Figure 1 shows skin blanching as a function of time for the oil-in-water cream with a composition given in Example 1, containing 25% propylene glycol, and the commercial water-in-oil cream Elocon® 0.1% cream. The skin is exposed to thecreams 5 hours prior to evaluation (results from Example 2). -
Figure 2 shows skin blanching as a function of time for oil-in-water creams, containing 20% (PG:W of 1:2.8) and 30% (PG:W of 1:1.5) propylene glycol, and the commercial water-in-oil cream Elocon® 0.1% cream. The skin is exposed to thecreams 6 hours prior to evaluation (results from Example 2). -
Figure 3 shows skin blanching as a function of time for oil-in-water creams containing 20% oil/fat mainly coconut oil (includes all ingredients with HLB ≤ 11) and 20% propylene glycol (90016-0712-14); 40% oil/fat mainly paraffin oil and white soft paraffin (includes all ingredients with HLB ≤ 11) and no propylene glycol (90016-0711-47). The skin is exposed to thecreams 6 hours prior to evaluation (results from Example 2). -
Figure 4 . Mean AUC of baseline-corrected, untreated control site-corrected values and 95% confidence intervals (Per Protocol Population) - results from Example 2. -
Figure 5 shows skin blanching as a function of time for oil-in-water creams containing i) 25% propylene glycol and 20% coconut oil (weight ratio PG:W of 1:1.58) and ii) the composition described in table 1 herein (PG:W of 1:2.06), and the commercial water-in-oil cream Elocon® 0.1% cream. The skin is exposed to thecreams 6 hours prior to evaluation - results from Example 3. -
Figure 6 shows skin blanching as a function of time for a cream according to the invention compared with Elocon® 0.1% cream and creams prepared according to examples 3 and 5, respectively, ofWO 2008/126076 (in short: Perrigo creams). PG:W of Perrigo creams is 1:3.6. - The invention is further illustrated in the following non-limiting examples.
- The complete composition of the 0.1 % mometasone furoate oil-in-water cream is given in table 1.
Table 1. Complete composition of 0.1 % mometasone furoate oil-in-water cream. Name of ingredient Quantity (mg/g) Function Concentration range (mg/g) Replacement Active substance Mometasone furoate, micronized 1.0 Drug substance 0.10 - 2.0 - 100% ≤ 20 µm 99% ≤ 15 µm 80% ≤ 5 µm Excipients Coconut oil 80 Emollient 30 - 300 Vegetable oil/fat, animal oil/fat, mineral oil, ester oil or wax, silicon oil Stearic acid 20 Emulsifying agent 10-50 glycerol alkyl esters, macrogol alkyl esters, polyoxyethyleneglycol alkyl esters, fatty acids, polyoxyethylene sorbitan esters, polyoxyethylene alkyl ethers, galactolipids Macrogol Stearate 30 Emulsifying agent Solubilizer of drug substance 10-50 Glycerol monostearate 40-55 30 Emulsifying agent 10-50 Cetostearyl alcohol 70 Viscosity-increasing agent 50-150 Fatty alcohols Propylene glycol 250 Solvent Solubilizer of drug substance 200 - 450 Sodium citrate 2.7 pH regulating agent 1 - 10 hydrochloric acid, phosphoric acid, sodium hydroxide, citrate buffer, phosphate buffer, phthalate buffers, acetate buffers, succinate buffers Citric acid, monohydrate 2.5 pH regulating agent Water, purified Ad 1 g Solvent - - - Mometasone furoate is dispersed in a small portion of a propylene glycol and water mixture. The remaining parts of propylene glycol and water are mixed and heated to about 65°C together with sodium citrate and citric acid. Thereafter, the dispersion of mometasone furoate is added to the aqueous phase.
- The ingredients of the oil phase (coconut oil, stearic acid, cetostearyl alcohol, macrogol stearate) are mixed and heated to about 70°C.
- The oil phase is added to the aqueous phase. The emulsion is mixed and homogenized and thereafter the cream is cooled during stirring.
-
- 1. Mometasone furoate dispersion.
Mix a small, suitable amount of 2 parts purified water and 1 part propylene glycol in a vessel. Add mometasone furoate to the vessel. Stir the mixture for 5 minutes, until the active substance is dispersed. - 2. Mixing and heating of water phase to clear solution.
Add sodium citrate, citric acid monohydrate, propylene glycol and purified water to a vessel. Heat to 65°C ± 5°C during mixing at low speed. Control that a clear solution is obtained. - 3. Addition of the mometasone furoate dispersion to the water phase.
Add the dispersed active substance to the water phase. - 4. Add raw material to oil phase.
Add all the raw materials of the oil phase to a vessel. - 5. Melting and heating of oil phase
Heat and melt the oil phase to 70°C ± 5°C. - 6. Mixing to homogeneous solution.
Control that the oil phase is a homogeneous solution. - 7. Transfer the oil phase to the water phase.
Transfer all the oil phase to the water phase. - 8. Mixing.
Mix the two phases until a white emulsion has emerged. Use medium mixing speed. - 9. Add vacuum.
Carefully add vacuum. - 10. Homogenisation.
Homogenize the emulsion for about 5 - 10 minutes, while stirring. - 11. Cooling.
Cool the emulsion while stirring, until the temperature of the emulsion reaches 25°C. - 12. Final mixing.
When the cream (emulsion) has reached a temperature of 25°C, mix for additional 15 minutes at low speed. - After storage at 25°C/60% RH and 40°C/75% RH for up to 9 months, the 0.1 % mometasone furoate oil-in-water cream is stable both chemically and physically, see table 2 and 3.
- Samples with the composition according to table 1 but with 20 % (w/w) propylene glycol have been stored at 25°C/60%RH and 40°C/75%RH. Stability data is available for up to 12 months, see table 4 and 5. Data shows that the composition is stable at both temperatures for the investigated period.
Table 2 Stability data after storage of the composition according to table 1, Mometasone furoate 0.1% cream, batch No. 90016-0806-07, at 25°C/60% RH in aluminum laminated co-extruded PE 100 g tubes. pH Related substances Storage Months Appearance Assay, mometasone furoate % (m/m) Unknown RRT=0.77 area-% Unknown RRT=1.03 area-% Unknown RRT=1.07 area-% Sum of related substances area-% 0 Complies 4.7 0.098 <0.10 <0.10 0.10 0.10 3 Complies 4.5 0.098 <0.10 <0.10 0.11 0.11 6 Complies 4.6 0.099 <0.10 <0.10 0.11 0.11 9 Complies 4.6 0.099 <0.10 <0.10 0.11 0.11 Table 3 Stability data after storage of the composition according to table 1, Mometasone furoate 0.1 % cream, batch No. 90016-0806-07, at 40°C/75% RH in aluminum laminated co-extruded PE 100 g tubes. pH Related substances Storage Months Appearance Assay, mometasone furoate % (m/m) Unknown RRT=0.77 area-% Unknown RRT=1.03 area-% Unknown RRT=1.07 area-% Sum of related substances area-% 0 Complies 4.7 0.098 <0.10 <0.10 0.10 0.10 3 Complies 4.5 0.097 <0.10 0.12 0.10 0.22 6 Complies 4.5 0.098 <0.10 0.18 0.10 0.28 Table 4 Stability data after storage of the composition according to table 1 but with 20 % (w/w) propylene glycol, Mometasone furoate 0.1% cream, batch No. 90016-0712-14, at 25°C/60% RH in 30 g aluminum tubes. pH Related substances Storage Months Appearance Assay, mometasone furoate % (m/m) Unknown RRT=0.77 area-% Unknown RRT=1.03 area-% Unknown RRT=1.07 area-% Sum of related substances area-% 0 Complies 4.6 0.100 <0.10 <0.10 <0.10 <0.10 1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. 4 Complies 4.6 0.103 <0.10 <0.10 <0.10 <0.10 6 Complies 4.8 0.100 <0.10 <0.10 0.10 0.10 12 Complies 4.6 0.102 <0.10 <0.10 0.11 0.11 n.a.= not analysed Table 5 Stability data of the composition according to table 1 but with 20 % (w/w) propylene glycol, Mometasone furoate 0.1% cream, batch No. 90016-0712-14, after storage at 40°C/75% RH in 30 g aluminum tubes. Related substances Storage Months Appearance pH Assay, mometasone furoate % (m/m) Unknown RRT=0.77 area-% Unknown RRT=1.03 area-% Unknown RRT=1.07 area-% Sum of related substances area-% 0 Complies 4.6 0.100 <0.10 <0.10 <0.10 <0.10 1 Complies 4.7 0.101 <0.10 <0.10 <0.10 <0.10 3 Complies 4.7 0.105 <0.10 <0.10 <0.10 <0.10 6 Complies 4.8 0.100 <0.10 0.16 0.10 0.26 - Skin blanching has been evaluated to assess the topical bioavailability of the 0.1 % mometasone furoate oil-in-water cream given in Example 1, see
Figure 1 . The blanching effect has been compared to Elocon® 0.1 % cream. Elocon® 0.1 % cream is a water-in-oil emulsion, containing 0.1 % mometasone furoate. Infigure 1 , it can be seen that the skin blanching and thereby the bioavailability of the 0.1 % mometasone furoate oil-in-water cream is comparable to that of Elocon® 0.1 % cream. - In
figure 2 , skin blanching after applying 0.1 % mometasone furoate oil-in-water creams containing 20 % and 30 % propylene glycol was compared with Elocon® 0.1 % cream. Also for these creams the skin blanching was comparable to that of Elocon® 0.1 % cream. The creams employed has a PG:W ratio of from 1:1.5 to 1:2.8. - The effect on skin blanching after applying an oil-in-water cream with a high fat content (40 %) and no propylene glycol was compared with the effect of a cream with 20 % propylene glycol and 20 % fat, see
figure 3 . It can be seen that the presence of propylene glycol in the formulations is more important than a high fat content. - In the in-vivo screening studies, approximately 40 mg of each cream was applied to a 2.25 cm2 test field located on the volar part of the forearm. The non-occlusive application was removed after 5 hours (
figure 1 ) or6 hours (figure 2 and3 ) exposure of the creams. Prior to the creams were applied, the skin color was determined by comparing the color of the test field with shades in a color atlas (Natural Color System SS019102, 2nd ed.). White is given an index of 4 (color 0502-Y) and untreated skin color on this object gave an index of 0 (color S10-C20-Y50R). - A vasoconstrictor assay (VCA) study on 30 healthy subjects, vehicle controlled single-center double blind study for the study preparations (Mometasone furorate 0.1% cream, Galenica (the invention) and Elocon generic copy, class III) observer-blind for the comparators (Kenacort-T 0.1% cream, Elocon® 0.1% cream and Dermovat 0.05% cream, class II, III and IV respectively) was performed. Approximately 50 µl cream was applied to a total of nine test fields of 2 cm2 each, located on the volar surface of the forearms, non-occlusive for 6 hours. The skin color was measured prior to treatment (baseline) and after 1, 2, 4, 6, 18 and 24 hours after the end of the treatment period with a Minolta Chroma-Meter CR-300. The total mean skin blanching was assessed as baseline corrected AUC for the tested creams according to
figure 4 . - The result shows that topical bioequivalence is possible to obtain with the described o/w cream when compared to the Elocon® w/o cream.
- The 0.1 % mometasone furoate oil-in-water cream has been challenge tested according to Ph. Eur. "Efficacy of Antimicrobial Preservation". The o/w cream showed that the formulation satisfies criteria in Ph. Eur. 5.1.3. Hence, the product is self preserved and has antimicrobial properties.
- Two compositions of the present invention and Elocon® 0.1 % were tested as described in Example 2 above. The compositions of the invention had different weight ratios PG:W, namely from 1:1.6 to 1:2.1. The composition with the weight ratio 1:1.6 was in accordance with the composition described in Table 1 herein, but contained 20% w/w coconut; the content of water was reduced accordingly. The composition with the weight ratio 1:2.1 contained 25% propylene glycol and had a composition as described in Table 1 herein.
- The results show that both compositions have therapeutic effects similar to that of Elocon® cream.
- As mentioned in the introduction herein, an oil-in-water composition of mometasone has been described in
WO 2008/126076 . However, no in vivo studies have been reported. In order to compare the in vivo behaviour of compositions according to the present invention with those ofWO 2008/126076 (denoted Perrigo creams), a comparison study was made. - The compositions described in Example 3 (Formula B) and Example 5 (Formula C) were prepared as follows:
Composition Perrigo Mometasone furoate 0.1 % cream (comparative cream according toWO 2008/126076 )Formula B (Comparative) in patent WO2008/126076 Ingredients Concentration (wt%) Mometasone furoate 0.1 Phosphoric acid 0.525 Purified water 53.7 Xanthan gum 0.2 Carbomer 940 0.3 Dibasic sodium phosphate anhydrous (corresponding to 1.0 wt % heptahydrate) 0.53 Emulsifying wax (Polawax) 8.0 Benzyl alcohol 1.0 Propylene glycol 15.0 Cetostearyl alcohol 7.0 Oleic acid 1.2 Caprylic capric triglyceride 12.0 Formula C (Invention) in patent WO2008/126076 Ingredients Concentration (wt%) Mometasone furoate 0.075 Xanthan gum 0.2 Carbomer 940 0.3 Dibasic sodium phosphate anhydrous (corresponding to 1.0 wt % heptahydrate) 0.53 Emulsifying wax (Polawax) 8.0 Benzyl alcohol 1.0 Propylene glycol 15.0 Cetostearyl alcohol 7.0 Oleic acid 1.2 Caprylic capric triglyceride 12.0 Phosphoric acid 0.525 Purified water 53.7 - The water phase is prepared first: Xanthan gum and carbomer 940 are dispersed in purified water. Next dibasic sodium phosphate is mixed into the dispersion. Emulsifying wax and benzyl alcohol are added to the dispersion and heated.
- To prepare the active solution, mometasone furoate is dissolved in heated propylene glycol.
- Next the oily phase is prepared: Oleic acid, cetostearyl alcohol, and caprylic capric triglyceride are combined and mixed.
- The active solution and the oily phase are added to the water phase.
- The resulting emulsion is cooled. pH is adjusted with phosphoric acid.
- The Perrigo compositions and a composition according to the present invention and Elocon® 0.1% cream were subjected to the skin blanching study described in Example 2 above and the results are reported in
Figure 6 . The results clearly demonstrate that the Perrigo creams do not lead to similar therapeutic effect as the Elocon® cream, whereas a composition of the invention has similar therapeutic effect as Elocon® cream.
Claims (17)
- An oil-in-water emulsion comprising mometasone or mometasone furoate and propylene glycol, and the concentration of propylene glycol is from 20 to 45% w/w, wherein a part of mometasone or mometasone furoate is present in undissolved form.
- An oil-in-water emulsion according to claim 1, wherein the weight ratio between the propylene glycol and water contained in the oil-in-water emulsion is from 1:1 to 1:3.
- An oil-in-water emulsion according to any of the preceding claims, wherein mometasone or mometasone furoate is the sole therapeutically active ingredient.
- An oil-in-water emulsion according to any of the preceding claims, wherein mometasone or mometasone furoate is present in the emulsion in micronised form.
- An oil-in-water emulsion according any of the preceding claims wherein the oil is a vegetable oil.
- An oil-in-water emulsion according to claim 5, wherein the vegetable oil is coconut oil, olive oil, sunflower oil and/or canola oil.
- An oil-in-water emulsion according to any of claims 5 to 6, wherein the concentration of the oil in the o/w emulsion is from about 3 to 30% w/w.
- An oil-in-water emulsion according to any of the preceding claims further comprising one or more emulsifying agents.
- An oil-in-water emulsion according to claim 8, wherein the one or more emulsifying agents are selected from the group consisting of glycerol alkyl esters, macrogol alkyl esters, polyoxyethyleneglycol alkyl esters, fatty acids, polyoxyethylene sorbitan esters, polyoxyethylene alkyl ethers, galactolipids.
- An oil-in-water emulsion according to claims 8 to 9, wherein the one or more emulsifying agents are glycerol monostearate 40-55, macrogol stearate, or stearic acid.
- An oil-in-water emulsion according to the preceding claims further comprising a viscosity-increasing agent.
- An oil-in-water emulsion according to claim 11, wherein the one or more viscosity-increasing agent is cetostearyl alcohol.
- An oil-in-water emulsion according to any of the preceding claims containing:0.05-0.2 % w/w of mometasone or mometasone furoate20-45 % w/w of propylene glycol,3-30 % w/w of a vegetable oil,1-15 % w/w of one or more emulsifying agents,optionally 0.1-1% w/w of a pH adjusting agent,optionally 5-15% w/w viscosity increasing agent,up to 100% w/w of water.
- An oil-in-water emulsion according to any of the preceding claims containing:0.06-0.15 % w/w of mometasone or mometasone furoate20-40 % w/w of propylene glycol,5-15 % w/w of a vegetable oil,1-10 % w/w of one or more emulsifying agents,0.1-1% w/w of a pH adjusting agent to adjust pH of the emulsion to about 4-6,optionally 5-15% w/w viscosity increasing agent,up to 100% w/w of water.
- An oil-in-water emulsion according to any of the preceding claims containing:0.1 % w/w of mometasone or mometasone furoatefrom 20 to 30 % w/w of propylene glycol,from 5 to 10 % w/w of a vegetable oil,from 5-10 % w/w of one or more emulsifying agents,0.1-1% w/w of a pH adjusting agent to adjust pH of the emulsion to about 4-6,5-10% w/w viscosity increasing agent,up to 100% w/w of water.
- An oil-in-water emulsion according to any of the preceding claims with the proviso that the emulsion does not contain one or more preservatives apart from the any preservative effect relating to the propylene glycol.
- An oil-in-water emulsion containing:
Name of ingredient Quantity (mg/g) Active substance Mometasone furoate, micronized 1.0 100% ≤ 20 µm 99% ≤ 15 µm 80% ≤ 5 µm Excipients Coconut oil 80 Stearic acid 20 Macrogol Stearate 30 Glycerol monostearate 40-55 30 Cetostearyl alcohol 70 Propylene glycol 250 Sodium citrate 2.7 Citric acid, monohydrate 2.5 Water, purified Ad 1g
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15172934.0A EP2962688B1 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
PL15172934T PL2962688T3 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
SI201031007T SI2429510T1 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
PL10721697T PL2429510T3 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
CY20151100770T CY1116667T1 (en) | 2009-05-12 | 2015-09-03 | WATER OIL EMULSION IN MOMETAZON AND PROPYLENGYCL WATER |
HRP20150959TT HRP20150959T1 (en) | 2009-05-12 | 2015-09-11 | Oil-in-water emulsion of mometasone and propylene glycol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200900601 | 2009-05-12 | ||
PCT/EP2010/002921 WO2010130428A1 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15172934.0A Division EP2962688B1 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2429510A1 EP2429510A1 (en) | 2012-03-21 |
EP2429510B1 true EP2429510B1 (en) | 2015-06-24 |
Family
ID=42352732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15172934.0A Active EP2962688B1 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
EP10721697.0A Active EP2429510B1 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15172934.0A Active EP2962688B1 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion of mometasone and propylene glycol |
Country Status (20)
Country | Link |
---|---|
US (2) | US8728497B2 (en) |
EP (2) | EP2962688B1 (en) |
JP (2) | JP5833541B2 (en) |
CN (1) | CN102458382B (en) |
AU (1) | AU2010246613B2 (en) |
BR (1) | BRPI1010907B8 (en) |
CA (1) | CA2761739C (en) |
CY (1) | CY1116667T1 (en) |
DK (1) | DK2429510T3 (en) |
ES (2) | ES2813400T3 (en) |
HR (1) | HRP20150959T1 (en) |
HU (1) | HUE027718T2 (en) |
MX (1) | MX345888B (en) |
NZ (1) | NZ596429A (en) |
PL (2) | PL2429510T3 (en) |
PT (1) | PT2429510E (en) |
RU (1) | RU2526911C2 (en) |
SI (1) | SI2429510T1 (en) |
SM (1) | SMT201500297B (en) |
WO (1) | WO2010130428A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX345888B (en) | 2009-05-12 | 2017-02-22 | Galenica Ab * | Oil-in-water emulsion of mometasone and propylene glycol. |
PT105982B (en) * | 2011-11-03 | 2014-07-29 | Laboratório Edol Produtos Farmac Uticos S A | COMPOSITION AND METHOD OF COLD PREPARATION OF AN EMULSION USED AS A VEHICLE OF ANTI-INFLAMMATORY DRUGS |
WO2019082873A1 (en) * | 2017-10-23 | 2019-05-02 | マルホ株式会社 | Coating-forming topical agent |
US20190282465A1 (en) * | 2018-03-19 | 2019-09-19 | Essential Lipid Technologies, LLC | Topical Phospholipid Formulations and Methods for Preparing the Same |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4282216A (en) * | 1977-04-20 | 1981-08-04 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
US4808610A (en) | 1986-10-02 | 1989-02-28 | Schering Corporation | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
US5422361A (en) * | 1989-12-20 | 1995-06-06 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
WO1994013257A1 (en) * | 1992-12-16 | 1994-06-23 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
US5696105A (en) * | 1996-03-14 | 1997-12-09 | Hackler; Walter A. | Antifungal nail composition |
US5952003A (en) * | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US7030203B2 (en) * | 2001-09-28 | 2006-04-18 | 3M Innovative Properties Company | Water-in-oil emulsions with ethylene oxide groups, compositions, and methods |
PE20030828A1 (en) * | 2002-03-04 | 2003-11-04 | Novartis Ag | OPHTHALMIC COMPOSITION INCLUDING ASCOMYCIN |
TR200201343A2 (en) | 2002-05-17 | 2003-12-22 | Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Pharmaceutical composition containing corticosteroid and antiseptic |
DE60318727T2 (en) | 2002-08-27 | 2009-01-08 | Schering Corp. | METHOD FOR PRODUCING DOSAGE INHALER FORMULATIONS |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
EP1624861A2 (en) | 2003-05-23 | 2006-02-15 | Taro Pharmaceuticals Industries Ltd. | Novel topical steroid cream formulations |
US20070179152A1 (en) | 2003-05-23 | 2007-08-02 | Lee Margaret S | Combination therapy for the treatment of neoplasms |
US20050196462A1 (en) * | 2003-12-30 | 2005-09-08 | Oculus Innovative Sciences, Inc. | Topical formulation containing oxidative reductive potential water solution and method for using same |
US20070099883A1 (en) * | 2005-10-07 | 2007-05-03 | Cheryl Lynn Calis | Anhydrous mometasone furoate formulation |
DE102006034883A1 (en) | 2006-07-25 | 2008-01-31 | Hermal Kurt Herrmann Gmbh & Co. Ohg | Composition, useful to treat inflammatory skin disease, e.g. psoriasis, comprises mometasone furoate, water, a combination of aromatic alcohol and a solvent e.g. alkoxylated fatty-alcohol and/or aliphatic alcohol, and further additives |
WO2008126076A2 (en) * | 2007-04-11 | 2008-10-23 | Perrigo Israel Pharmaceuticals Ltd. | Low-dose mometasone formulations |
DK2429490T3 (en) | 2009-05-12 | 2017-02-20 | Galenica Ab | OIL-IN-WATER EMULSION OF MOMETASON |
MX345888B (en) | 2009-05-12 | 2017-02-22 | Galenica Ab * | Oil-in-water emulsion of mometasone and propylene glycol. |
-
2010
- 2010-05-12 MX MX2011011959A patent/MX345888B/en active IP Right Grant
- 2010-05-12 HU HUE10721697A patent/HUE027718T2/en unknown
- 2010-05-12 PL PL10721697T patent/PL2429510T3/en unknown
- 2010-05-12 ES ES15172934T patent/ES2813400T3/en active Active
- 2010-05-12 AU AU2010246613A patent/AU2010246613B2/en active Active
- 2010-05-12 CN CN201080030169.1A patent/CN102458382B/en active Active
- 2010-05-12 DK DK10721697.0T patent/DK2429510T3/en active
- 2010-05-12 WO PCT/EP2010/002921 patent/WO2010130428A1/en active Application Filing
- 2010-05-12 PL PL15172934T patent/PL2962688T3/en unknown
- 2010-05-12 PT PT107216970T patent/PT2429510E/en unknown
- 2010-05-12 CA CA2761739A patent/CA2761739C/en active Active
- 2010-05-12 JP JP2012510162A patent/JP5833541B2/en active Active
- 2010-05-12 EP EP15172934.0A patent/EP2962688B1/en active Active
- 2010-05-12 RU RU2011150246/15A patent/RU2526911C2/en active
- 2010-05-12 SI SI201031007T patent/SI2429510T1/en unknown
- 2010-05-12 NZ NZ596429A patent/NZ596429A/en not_active IP Right Cessation
- 2010-05-12 ES ES10721697.0T patent/ES2547556T3/en active Active
- 2010-05-12 EP EP10721697.0A patent/EP2429510B1/en active Active
- 2010-05-12 US US13/319,758 patent/US8728497B2/en active Active
- 2010-05-12 BR BRPI1010907A patent/BRPI1010907B8/en active IP Right Grant
-
2014
- 2014-02-24 US US14/187,997 patent/US11395827B2/en active Active
-
2015
- 2015-07-16 JP JP2015142118A patent/JP2015227354A/en active Pending
- 2015-09-03 CY CY20151100770T patent/CY1116667T1/en unknown
- 2015-09-11 HR HRP20150959TT patent/HRP20150959T1/en unknown
- 2015-11-30 SM SM201500297T patent/SMT201500297B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60014162T2 (en) | FENO-FIBRATED GALENIC DRUG COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF | |
EP1993515B1 (en) | Method for solubilizing, dispersing, and stabilizing materials, products manufactured according to said method, and use thereof | |
WO1993000106A1 (en) | External preparation containing cyclosporin | |
US11395827B2 (en) | Oil-in-water emulsion of mometasone and propylene glycol | |
US20220331238A1 (en) | Oil-in-water emulsion of mometasone | |
EP2952194B1 (en) | Emulsion composition | |
AU743486B2 (en) | Creams containing vitamin D3 derivatives | |
US20230123488A1 (en) | Stable topical tetracycline compositions | |
WO2007086582A1 (en) | OIL-IN-WATER TYPE EMULSION LOTION CONTAINING 22-OXA-1α,25-DIHYDROXYVITAMIN D3 AND METHOD OF TREATING SKIN DISEASE BY USING THE SAME | |
EP4108235B1 (en) | Topical pharmaceutical formulation | |
JP4060347B2 (en) | Oil-in-water emulsion lotion containing 22-oxa-1α, 25-dihydroxyvitamin D3 | |
JP2003073276A (en) | Stabilized anti-inflammatory ointment | |
EP2917177A1 (en) | Beta carotene preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20111212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20120910 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150209 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 732598 Country of ref document: AT Kind code of ref document: T Effective date: 20150715 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010025420 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20150959 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20150921 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2547556 Country of ref document: ES Kind code of ref document: T3 Effective date: 20151007 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20150907 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20150959 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E010964 Country of ref document: EE Effective date: 20150923 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20150401776 Country of ref document: GR Effective date: 20151022 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 19398 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 732598 Country of ref document: AT Kind code of ref document: T Effective date: 20150624 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010025420 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
26N | No opposition filed |
Effective date: 20160329 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E027718 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: HC9C |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20150624 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20150959 Country of ref document: HR Payment date: 20190412 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20150959 Country of ref document: HR Payment date: 20200415 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20200416 Year of fee payment: 11 Ref country code: MC Payment date: 20200525 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BG Payment date: 20200528 Year of fee payment: 11 Ref country code: SK Payment date: 20200428 Year of fee payment: 11 Ref country code: SM Payment date: 20200623 Year of fee payment: 11 Ref country code: SI Payment date: 20200415 Year of fee payment: 11 Ref country code: HU Payment date: 20200506 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20200507 Year of fee payment: 11 Ref country code: MK Payment date: 20200415 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AL Payment date: 20200507 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20150959 Country of ref document: HR Payment date: 20210511 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 19398 Country of ref document: SK Effective date: 20210512 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210513 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210512 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210512 Ref country code: SM Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211213 Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211130 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210513 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20220125 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20150959 Country of ref document: HR Payment date: 20220412 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20150959 Country of ref document: HR Payment date: 20230419 Year of fee payment: 14 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230526 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: RO Payment date: 20230421 Year of fee payment: 14 Ref country code: PT Payment date: 20230412 Year of fee payment: 14 Ref country code: NO Payment date: 20230516 Year of fee payment: 14 Ref country code: NL Payment date: 20230511 Year of fee payment: 14 Ref country code: LT Payment date: 20230420 Year of fee payment: 14 Ref country code: IT Payment date: 20230524 Year of fee payment: 14 Ref country code: IE Payment date: 20230508 Year of fee payment: 14 Ref country code: FR Payment date: 20230516 Year of fee payment: 14 Ref country code: ES Payment date: 20230609 Year of fee payment: 14 Ref country code: EE Payment date: 20230525 Year of fee payment: 14 Ref country code: DK Payment date: 20230515 Year of fee payment: 14 Ref country code: DE Payment date: 20230524 Year of fee payment: 14 Ref country code: CZ Payment date: 20230418 Year of fee payment: 14 Ref country code: CH Payment date: 20230602 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230426 Year of fee payment: 14 Ref country code: SE Payment date: 20230516 Year of fee payment: 14 Ref country code: PL Payment date: 20230417 Year of fee payment: 14 Ref country code: LV Payment date: 20230523 Year of fee payment: 14 Ref country code: IS Payment date: 20230517 Year of fee payment: 14 Ref country code: HR Payment date: 20230419 Year of fee payment: 14 Ref country code: GR Payment date: 20230525 Year of fee payment: 14 Ref country code: FI Payment date: 20230512 Year of fee payment: 14 Ref country code: AT Payment date: 20230524 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20230511 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230523 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20150959 Country of ref document: HR Payment date: 20240412 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20240516 Year of fee payment: 15 |